Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reveals strong agreement and interest, as seen in phrases like 'superior to enoxaparin,' 'low bleeding risk,' and 'may change practice,' which demonstrate excitement and support. Posts often reference detailed data, mechanisms, and future implications, reflecting deep engagement and recognition of the article's possible profound impact on thrombosis prevention.
Most discussions express strong support and excitement for the promising results of abelacimab, highlighting its superiority over traditional treatments like enoxaparin.
There is high curiosity and enthusiasm among posters about the new anticoagulant mechanism, with many eager to see future clinical applications.
Multiple posts reference specific data, mechanisms, and implications, indicating deep involvement with the research details.
The discussions suggest a significant potential to change current standards in VTE prevention, with many considering it a potential game-changer in thrombosis management.
Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
Abelacimab for Prevention of Venous Thromboembolism | NEJM novi, bezbedniji i efikasniji put u prevenciji venskog tromboembolizma. Blokada XI faktora koagulacije. Manje tromboza i manje krvarenja nakon zamene kolena. https://t.co/MmFNLyzTWG
@Bloodman https://t.co/vxBpZjhBd1 When do you think we shall see them in the clinic ?
Abelacimab (Factor XI mAb) IV x 1 post-op knee arthroplasty at 75mg (5%) or 150mg (4%) led to fewer VTE 30d-events vs enoxaparin 40mg sc daily (22%) w ~similar bleeding rates in open-label parallel-group N=412 study https://t.co/B2tbXK4BfX @NEJM @Anthos_Tx @blackstone @Novartis
#Abelacimab: new entry to prevent #DVT #cardiotwitter https://t.co/dvnbHBfsBy
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/QSs4uZpfmh やはりXI阻害薬が次の世代の抗凝固薬になれるかな？
Abelacimab for Prevention of Venous Thromboembolism | New England Journal of Medicine https://t.co/QoBpZbQyWv
21c) Ph 2 data with #abelacimab, a monoclonal antibody to #FXI and FXIa, demonstrate efficacy in the TKR population with no safety signals
21c) Ph 2 data with #abelacimab, a monoclonal antibody to #FXI and FXIa, demonstrate efficacy in the TKR population with no safety signals
@sciencescanner @BiotechObserver no evidence that it reduces thrombosis? and what is that? Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/hLjQ1ifH1B https://t.co/S9rF0YVwgq
RT @cardiomet_CE: 13) A little more about #abelacimab (following up on slide 9c): It is a highly selective, fully humanized monoclonal anti…
13) A little more about #abelacimab (following up on slide 9c): It is a highly selective, fully humanized monoclonal antibody #Mab with no evidence of off-
Abelacimab for Prevention of Venous Thromboembolism https://t.co/jHFEDMEy7Q Abelacimab use in percutaneous intervention in ESRD patients?? #antiThrombotic https://t.co/y9YMRzBmY8
RT @ethanjweiss: On brief hiatus but wanted to share this remarkable result for novel anti-factor XI ab program from Anthos. Exciting pot…
@anflan88 Previously https://t.co/B2tbXK4BfX
Pretty big news. Better AC with less bleeding. Of note, abelacimab was previously shown to reduce VTE after TKA up to 80% compared to LVX (although these were asymptomatic and VTE rates were way higher than we typically see). https://t.co/5XpcfsdOfp #orthotwitter https://t.co/qTePzs1UY5
https://t.co/YxctrbsTTu
Citation: Verhamme, Peter, et al. "Abelacimab for prevention of venous thromboembolism." New England Journal of Medicine 385.7 (2021): 609-617.
RT @cardiomet_CE: 23b) The primary efficacy outcome was #VTE, detected by mandatory venography of the ipsilat or objective confirmation of…
23b) The primary efficacy outcome was #VTE, detected by mandatory venography of the ipsilat or objective confirmation of symptomatic events. See
RT @JAlvikas: Have you ever wanted to give someone postop DVT prophylaxis without worrying about bleeding risk? Well, that future may not b…
Have you ever wanted to give someone postop DVT prophylaxis without worrying about bleeding risk? Well, that future may not be that far https://t.co/CtGDtmPbzQ
A single intravenous dose of abelacimab ( Novel Factor XI Inhibitor ) for Post-operative VTE prophylaxis was found to be superior to Levonox at a dose of 75 mg and 150 mg. https://t.co/56kdB7KBPz
RT @BijoyTelivala: @Bloodman https://t.co/vxBpZjhBd1 When do you think we shall see them in the clinic ?
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/lgnrYhQLhx
@Bloodman https://t.co/vxBpZjhBd1 When do you think we shall see them in the clinic ?
The Future may be here, would u give your AFib patient a single monthly SQ injection ? Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/uBqT71v9ZA
My favorite APPE journal club so far? https://t.co/8KT5dBuaMX https://t.co/sihSSY7JTG
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/WQyf2TjbRi
Abelacimab, a monoclonal antibody that binds to factor XI https://t.co/tibBi2hLaA
Fascinating mechanism. Has the potential to influence future VTE prophylaxis. Definitely a drug to keep on the radar https://t.co/D0c0qmyWUi
Abelacimab for Prevention of Venous Thromboembolism, Dr. Jeffrey Weitz, M.D. -@Cardio_KULeuven #VenousThromboembolism #Cardiology #Research https://t.co/r269GhrjGQ https://t.co/cknCUe4Vt4
Podcast- Abelacimab for Prevention of Venous Thromboembolism, Dr. Jeffrey Weitz, M.D. -@Cardio_KULeuven #VenousThromboembolism #Cardiology #Research Link to Audio- https://t.co/V2ko6imkIy https://t.co/rho2nxR5N3
Journal Club Today!
RT @traumamd1: Looks promising ... will this change VTE prophylaxis? Probably more questions than answers at this time. Abelacimab for Prev…
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/q7prNmldZa
RT @davidhenrymd: Abelacimab for Prevention of Venous Thromboembolism: A great article on postop DVT prophylaxis with a Factor XI inhibito…
RT @davidhenrymd: Abelacimab for Prevention of Venous Thromboembolism: A great article on postop DVT prophylaxis with a Factor XI inhibito…
RT @davidhenrymd: Abelacimab for Prevention of Venous Thromboembolism: A great article on postop DVT prophylaxis with a Factor XI inhibito…
Abelacimab for Prevention of Venous Thromboembolism: A great article on postop DVT prophylaxis with a Factor XI inhibitor https://t.co/tNVasIGtwa https://t.co/eSdtZMkKnl
Interesting….. https://t.co/NTSk4oJAhd
https://t.co/eXlsWJrVss Abelacimab superior to enoxaparin for DVT propylaxis
Abelacimab for Prevention of Venous Thromboembolism. A fascinating article on postop DVT prophylaxis with a Factor XI inhibitor. Interesting reading for all of us benign hematologists https://t.co/tNVasIGtwa https://t.co/CIqnZFCjBM
Abelacimab for Prevention of Venous Thromboembolism https://t.co/zmKYhx2OXu
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
#ClotPLUS: "Abelacimab for Prevention of Venous Thromboembolism." https://t.co/PvOwtez5aC #VTE #Thrombosis #Research #Clots https://t.co/D9zDOTKqoC
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/56f1nBwM1A
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
Big paper in the world of venous thromboembolism...https://t.co/zhhWsvaErn
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
RT @NEJM: Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
Visual Abstract - Abelacimab for Prevention of Venous Thromboembolism https://t.co/yJnGqln166 https://t.co/wxZ19VGrzb
New post in Development of Pharmacy Channel: Abelacimab for Prevention of Venous Thromboembolism https://t.co/3pKmslWkpB https://t.co/b48YKPYizS
Neat concept, an anti-factor XI mAb that could be a hemostasis-sparing anti-thrombotic The 22% VTE rate in the LMWH control seems high, but is presumably an artifact of dx by mandatory venography Curious about real-world NNT/NNH, other applications, $ https://t.co/BOTA1VLySS https://t.co/s0bQCwRZCV
This should be interesting. https://t.co/vbDEIKRKPx
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/1b1XdfXbxc
RT @ABsteward:
https://t.co/22YdZX91Bo https://t.co/frAI2kAZz4
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/azotMftlvw
VTE予防にもマブが。 #DVT #VTE Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/nekqmywO6h
A single IV dose of abelacimab (a mAb that inhibits factor XI) prevents VTE after total knee arthroplasty with a low risk of bleeding https://t.co/tBH01Rax87 https://t.co/q2iUbycQF0
Abelacimab for Prevention of Venous Thromboembolism - PubMed ファクターXI阻害薬 アベラシマブ https://t.co/7N1w8s4kwO
RT @slobadoktor: Abelacimab for Prevention of Venous Thromboembolism | NEJM novi, bezbedniji i efikasniji put u prevenciji venskog tromboem…
https://t.co/I5ILrdqM0w https://t.co/bywK0ZUdlx
Interesting data on abelacimab, mAb against FXI, for dvt prophy after arthroplasty. Low dose (30 mg) non inferior to enoxaparin, higher doses (75 mg,150 mg) superior. Low bleeding and clotting risk. But what to do with breakthrough VTE? https://t.co/99nxMF7RRR
y se ha estudiado su relación con la trombosis venosa profunda, el cual ha arrojado increíbles resultados en la prevención de trombosis venosa. 19 de julio de 2021 DOI: 10.1056 / NEJMoa2105872 https://t.co/jraSgdVazZ
Reading this and focusing on the control group like wow “22 % of knee replacement pt who received 40 mg of enoxaparin after knee replacement got a DVT”. Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/GpBkO80Q1e
Abelacimab for Prevention of Venous Thromboembolism | NEJM novi, bezbedniji i efikasniji put u prevenciji venskog tromboembolizma. Blokada XI faktora koagulacije. Manje tromboza i manje krvarenja nakon zamene kolena. https://t.co/MmFNLyzTWG
Abelacimab EV (anticorpo monoclonal que impede ativação do FXI) foi comparado em diferentes doses (30, 75 e 150mg) com enoxaparina 40mg SC em um estudo fase 2, randomizado e aberto, em pacientes submetidos a artroplastia de joelho https://t.co/eOpZCjLHuC
"Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding." https://t.co/Mj0ovxyeNU
Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. @NEJM @VerhammePeter https://t.co/bLkGcpUC5n
RT @sgoto4: Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/Cs104HXF0l XI inhibitors では日本企業は競争に参加できなそう。Xa阻害の時は頑張ったけ…
RT @danisevisan: Anticuerpo monoclonal para la prevención de TVP post IQ protesis rodilla. Tasa de eventos del 22% en el comparador enoxapa…
RT @sgoto4: Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/Cs104HXF0l XI inhibitors では日本企業は競争に参加できなそう。Xa阻害の時は頑張ったけ…
RT @biorheology333: Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/88DTgZEgyA 次世代の抗凝固薬になるか？XI阻害薬！
Abelacimab for Prevention of Venous Thromboembolism https://t.co/2BliHwFG2Z https://t.co/v77d8ZSrll
RT @biorheology333: Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/88DTgZEgyA 次世代の抗凝固薬になるか？XI阻害薬！
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/Cs104HXF0l XI inhibitors では日本企業は競争に参加できなそう。Xa阻害の時は頑張ったけど。
RT @biorheology333: Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/88DTgZEgyA 次世代の抗凝固薬になるか？XI阻害薬！
RT @SABOURETCardio: #Abelacimab: new entry to prevent #DVT #cardiotwitter https://t.co/dvnbHBfsBy
The new wave of anticoagulants are here: Factor XI inhibition for post-operative VTE prophylaxis. https://t.co/OpPQ0KKWJf
https://t.co/cVz4jL3OGS
RT @bryanacotton1: Monoclonal Ab that binds to factor XI superior to enoxaparin in VTE prevention in TKA. Still bothers me to see somethin…
Abelacimab vs. enoxaparin trial: Factor XI inhibition with a single IV dose of abelacimab after total knee arthroplasty was effective for the prevention of #VTE and was associated with a low risk of bleeding. @VerhammePeter @NEJM https://t.co/zTibNtByxQ https://t.co/sFrR4CGJin
"Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding" https://t.co/3j2duskcu8 https://t.co/uv1job4Yrj
RT @SABOURETCardio: #Abelacimab: new entry to prevent #DVT #cardiotwitter https://t.co/dvnbHBfsBy
#Abelacimab: new entry to prevent #DVT #cardiotwitter https://t.co/dvnbHBfsBy
RT @bryanacotton1: Monoclonal Ab that binds to factor XI superior to enoxaparin in VTE prevention in TKA. Still bothers me to see somethin…
人工膝関節全置換術後患者に対する，第XI因子に結合しザイモゲン（不活性前駆体）の状態にするモノクローナル抗体であるアベラシマブ単回静脈内投与は，エノキサパリン 40 mg を1日1回皮下投与するのと比較して，アベラシマブ 30mg では非劣性，75mg と 150mg では優れていた．https://t.co/A4HMWHJQCi
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/OCkFA84lsE
Very-interesting results, Factor XI antibody better compared to enoxaparin to prevent DVT. Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/wp4CwryZJ5
Monoclonal Ab that binds to factor XI superior to enoxaparin in VTE prevention in TKA. Still bothers me to see something reportedly better blood thinner (less VTE) AND less bleeding events.
Abelacimab (a monoclonal antibody that binds to factor XI and locks it in the inactive precursor conformation) for Prevention of Venous Thromboembolism | NEJM https://t.co/6Z6OHjm60Y
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/E4lr5GElTv
RT @MarcCarrier1: Presented as a late breaking abstract at #ISTH2021 and published in @NEJM Factor XI inhibition with abelacimab is effect…
Looks like Abelacimab is going to change the standard of care. #practicealert #postopcare #VTE #kneearthroplasty https://t.co/37fphZCnQ2
Abelacimab for Prevention of Venous #Thromboembolism | @NEJM #thrombosis @Bayer @BayerUS @ionispharma https://t.co/kt6qJmjk9k
*Abelacimab antagonista del factor XI en dosis de 75 y 150 mg demostró ser superior a enoxaparina 40 mg SC cada 12 horas, en prevención de TE post operatorio de remplazo de rodilla. https://t.co/PwVaQVGOUH https://t.co/qJnHVVnUwr
Las tasas de tromboembolismo venoso después de la artroplastia total de rodilla electiva favorecieron al monoclonal abelacimab sobre anticoagulante estándar enoxaparina (Lovenox) en ensayo de fase II. Abelacimab for Prevention of Venous Thromboembolism. https://t.co/Mw6IYLbjnc
RT @MarcCarrier1: Presented as a late breaking abstract at #ISTH2021 and published in @NEJM Factor XI inhibition with abelacimab is effect…
Abelacimab for Prevention of Venous Thromboembolism - https://t.co/xmTAWeVQJV https://t.co/I1IecUYKEa
RT @XBayona:
Glad to see the hematologist got their alphabet soup correct. Am I right, @DGlaucomflecken? Interested to see what larger and longer studies will show. https://t.co/Z9Kaz1IQnU
Abelacimab (Factor XI mAb) IV x 1 post-op knee arthroplasty at 75mg (5%) or 150mg (4%) led to fewer VTE 30d-events vs enoxaparin 40mg sc daily (22%) w ~similar bleeding rates in open-label parallel-group N=412 study https://t.co/B2tbXK4BfX @NEJM @Anthos_Tx @blackstone @Novartis
RT @cardiomet_CE: Kudos to @VerhammePeter and team . . . more support for anti-FXI/XIa as the next frontier in anticoagulant management! ht…
Anticuerpo monoclonal para la prevención de TVP post IQ protesis rodilla. Tasa de eventos del 22% en el comparador enoxaparina...diría que eso no refleja la realidad! https://t.co/9zIdLNiiCx
RT @cardiomet_CE: Kudos to @VerhammePeter and team . . . more support for anti-FXI/XIa as the next frontier in anticoagulant management! ht…
RT @TaniaAhuja: time to target other factors in the #CoagulationCascade
Abelacimab for Prevention of Venous Thromboembolism | NEJM - https://t.co/xmTAWeVQJV https://t.co/mcESFy1CnV
RT @cardiomet_CE: Kudos to @VerhammePeter and team . . . more support for anti-FXI/XIa as the next frontier in anticoagulant management! ht…
Kudos to @VerhammePeter and team . . . more support for anti-FXI/XIa as the next frontier in anticoagulant management! https://t.co/lFsCif6YWC @MAK_PhD
RT @TaniaAhuja: time to target other factors in the #CoagulationCascade
RT @sgoto4: Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/QSs4uZpfmh やはりXI阻害薬が次の世代の抗凝固薬になれるかな？
RT @ethanjweiss: On brief hiatus but wanted to share this remarkable result for novel anti-factor XI ab program from Anthos. Exciting pot…
RT @TaniaAhuja: time to target other factors in the #CoagulationCascade
Abelacimab for Prevention of Venous Thromboembolism https://t.co/HXlAQi5yge #abelacimab #prevention #factorXI @NEJM
(NEJM) Seguridad y eficacia de Abelacimab en la prevención del TEV postquirúrgico https://t.co/xwH3DDkVpU ECA https://t.co/vwMMoK5T27
RT @sanz_guille: Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/XONfjOYLny
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/XONfjOYLny
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/aKGIae2QzR
RT @TaniaAhuja: time to target other factors in the #CoagulationCascade
Abelacimab for Prevention of Venous Thromboembolism: factor XI is at least as important as tissue factor in the pathogenesis of post- operative venous thromboembolism | NEJM https://t.co/QFceZJWSdb
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/sLExIhTyNq
RT @DorotheeFaille: #ISTH2021 Late Breaking Abstract Anti-FXI Abelacimab for Prevention of Venous Thromboembolism @NEJM https://t.co/tioJkC…
RT @sgoto4: Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/QSs4uZpfmh やはりXI阻害薬が次の世代の抗凝固薬になれるかな？
Abelacimab for Prevention of Venous Thromboembolism | NEJM https://t.co/QSs4uZpfmh やはりXI阻害薬が次の世代の抗凝固薬になれるかな？
This study compared the efficacy and safety of the investigational drug Abelacimab, a monoclonal antibody targeting factor XI, to Enoxaparin for prevention ...
DOI: 10.1056/NEJMoa2105872. 栓塞的观察研究[J]. 中华心血管病杂志, 2013, 41(3): 224‑228. [67] Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus DOI ...
doi:10.1056/nejmoa2105872 patients with kidney failure undergoing hemodialysis: a randomized ... doi:10.1056/nejmoa1405760 venous thromboembolism with ...
doi: 10.1056/NEJMp030086 ment of venous thromboembolism in people ... Drug-drug interactions: implications for anticoagulation, with 10.1056/NEJMoa2105872
doi: 10.1056/NEJMoa2105872. PubMed. Verhamme P , ; ANT-005 TKA Investigators. Abelacimab for prevention of venous thromboembolism . N Engl J ...
... 10.1056/NEJMoa2105872) [6] Sterne JA, et al. Health Technol Assess. 2017;21(9):1-386 [7] Benner J, et al. Value in Health. 2023;26(6):S122 ...
... 10.1056/NEJMoa2105872) [6] Sterne JA, et al. Health Technol Assess. 2017;21(9):1-386 [7] Benner J, et al. Value in Health. 2023;26(6):S122 ...
... 10.1056/NEJMoa2105872) [v] TIMI Study Group website; AZALEA-TIMI 71 page (https://timi.org/azalea-timi-71/). TERMS AND PRIVACY_POLICY · Privacy ...
... www.nejm.org/doi/full/10.1056/NEJMoa2105872) [v] TIMI Study Group website; AZALEA-TIMI 71 page (https://timi.org/azalea-timi-71/)
... 10.1056/NEJMoa2105872?query=NC. Read next. How quickly does propranolol work? When propranolol is used to relieve performance, social, or ...
... 10.1056/NEJMoa2105872). 9u et al. J Am Coll Cardiol. Aug. 2021 (https://www.sciencedirect.com/science/article/abs/pii/S0735109721053213?via ...
... 10.1056/NEJMoa2105872. OCEANIC-AF https://classic.clinicaltrials.gov/ct2/show/NCT05643573. Will Factor XI Be the Goldilocks Anticoagulant ...
Verhamme P et al. New Engl J Med July 2021 (https://www.nejm.org/doi/full/10.1056/NEJMoa2105872); 2 Center for Disease Control and ...
doi:10.1056/NEJMoa2105872. Newsletter. Join thousands of clinicians staying current on new therapies, trial data, and expert insights ...
2021;doi:10.1056/NEJMoa2105872. Published by: cardiology today logo. Sources/Disclosures. Source: Press Release. Disclosures: Bloomfield is an ...
Abelacimab：第二阶段试验(2021) https://www.nejm.org/doi/full/10.1056/NEJMoa2105872 结论：“在全膝关节置换术后，单次静脉注射剂量的abelacimab ...
... 10.1056/NEJMoa2105872 WNIOSKI: „Inhibicja czynnika XI za pomocą pojedynczej dożylnej dawki abelacimabu po całkowitej artroplastyce kolana ...
Abelacimab: Fase II-studie (2021) https://www.nejm.org/doi/full/10.1056/NEJMoa2105872 KONKLUSJONER: "Faktor XI-hemming med en enkelt ...
Abelacimab: Phase II trial (2021) https://www.nejm.org/doi/full/10.1056/NEJMoa2105872 CONCLUSIONS: “Factor XI inhibition with a single ...
... 10.1056/NEJMoa2105872) 2 Yi BA et al. J Thromb Haemost. Oct. 2021 (https://pubmed.ncbi.nlm.nih.gov/34714969/). 條款 及 私隱政策 · Privacy ...
org/doi/full/10.1056/NEJMoa2105872) 7 Hsu et al. J Am Coll Cardiol. Aug. 2021 (https://www.sciencedirect.com/science/article/abs/pii ...
... 10.1056/NEJMoa2105872) 7 Hsu et al. J Am Coll Cardiol. Aug. 2021 (https://www.sciencedirect.com/science/article/abs/pii/S0735109721053213 ...
... 10.1056/NEJMoa2105872) iv Hsu et al. J Am Coll Cardiol. Aug. 2021 (https://www.sciencedirect.com/science/article/abs/pii/S0735109721053213 ...
... 10.1056/NEJMoa2105872. v Yi BA et al. J Thromb Haemost. Oct. 2021 https://pubmed.ncbi.nlm.nih.gov/34714969/. vi Hsu et al. J Am Coll Cardiol ...
... 10.1056/NEJMoa2105872) v Yi BA et al. J Thromb Haemost. Oct. 2021 (https://pubmed.ncbi.nlm.nih.gov/34714969/) vi Hsu et al. J Am Coll ...
... 10.1056/NEJMoa1915103) 4 Abdol Razak NB et al. Cancers (Basel) ... 10.1056/NEJMoa2105872) 11 Yi BA et al. J Thromb Haemost. Oct. 2021 ...
July 2021 (https://www.nejm.org/doi/full/10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021 (https://pubmed.ncbi.nlm.nih.gov ...
doi:10.1056/NEJMoa2105872; Safety and tolerability of abelacimab (MAA868) vs. rivaroxaban in patients with atrial fibrillation (AZALEA-TIMI ...
... 10.1056/NEJMoa1915103); Abdol Razak NB et al. Cancers (Basel) Oct ... 10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021 ...
... 10.1056/NEJMoa1915103); Abdol Razak NB et al. Cancers (Basel) Oct ... 10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021 ...
July 2021 (https://www.nejm.org/doi/full/10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021 (https://pubmed.ncbi.nlm.nih.gov ...
... 10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021 (https://pubmed.ncbi.nlm.nih.gov/34714969/); Hsu et al. J Am Coll Cardiol ...
... 10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021(https://pubmed.ncbi.nlm.nih.gov/34714969/); Hsu et al. J Am Coll Cardiol. Aug ...
(https://www.nejm.org/doi/full/10.1056/NEJMoa2105872); Fernandes CJ et al. Eur. Resp. Rev. 2019 (https://err.ersjournals.com/content/28/151/ ...
... 10.1056/NEJMoa2105872); Fernandes CJ et al. Eur. Resp. Rev. 2019 (https://err.ersjournals.com/content/28/151/180119); Agnelli G et al. New ...
... 10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021 (https://pubmed.ncbi.nlm.nih.gov/34714969/). Forward Looking Statements This ...
(https://www.nejm.org/doi/full/10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021 (https://pubmed.ncbi.nlm.nih.gov/34714969 ...
July 2021 (https://www.nejm.org/doi/full/10.1056/NEJMoa2105872); Yi BA et al. J Thromb Haemost. Oct. 2021 (https://pubmed.ncbi.nlm.nih.gov ...
org/10.1056/NEJMoa2105872. 《细胞》. 视网膜神经节细胞可保护视力. 美国 ... org/10.1056/NEJMoa2105872 《细胞》 视网膜神经节细胞可保护视力 ...
Allerdings wisse man nicht, wie wichtig Faktor XII bei der Entstehung von Thrombosen überhaupt ist. DOI: 10.1056/NEJMoa2105872. loading ...
Weitz. Abelacimab for Prevention of Venous Thromboembolism. New England Journal of Medicine, 2021; DOI: 10.1056/NEJMoa2105872. Cite This Page:.
2021;doi:10.1056/NEJMoa2105872. The findings illustrate the importance of factor XI in the development of postoperative VTE, researchers ...
doi.org/10.1056/NEJMoa2105872. Currently rated 2.5 by 2 people. Posted in: Medical Science News | Medical Research News | Medical Condition ...
N
S
BT
PN
S
SG
BA
CM
OC
BD
AM
D
EB
NV
AB
O
PS
JA
Sا
SM
SF
HR
RP
DV
TM
C
MP
JR
UH
TT
ME
SG
DH
SM
MJ
PM
MP
CN
ZJ
H
MM
J
MA
SM
CP
TM
HG
MT
MP
GH
RC
RK
A
うや
VP
GK
V
DP
も
NC
CP
DG
NN
D
DA
FM
SG
NH
P
EC
JF
EI
NA
PM
تا
MP
JB
GR
TB
FF
官H
KP
AG
猫
вп
D
ML
SM
AS
TT
LM
日情
SC
抗
MT
B
JS
RM
GR
M
ÁS
GZ
DS
AF
南P
MH
EP
BC
AM
HM
RM
BT
A
LM
MC
OG
N
AL
XB
AP
SB
DS
PV
SA
SM
D秋
RP
NG
DM
R
US
GS
C
LL
RG
AM
J
Tね